Do Either Corticosteroids or Antiviral Agents Reduce the Risk of Long-Term Facial Paresis in Patients with New-Onset Bell's Palsy?


      Background: The cause of Bell's palsy remains uncertain, although accumulating evidence suggests a viral etiology. To date, treatment to minimize long-term deficits from this disorder typically includes anti-inflammatory or antiviral medication. Clinical Question: Do corticosteroids or antiviral agents, either alone or in combination, reduce the risk of long-term facial paresis in patients with new-onset Bell's palsy? Evidence Review: Three multicenter, randomized, controlled trials enrolled over 1500 adult patients with paroxysmal, unilateral paresis of cranial nerve VII and treated them with varying regimens and combinations of prednisolone, antiviral agents, and placebo, and evaluated complete recovery up to 12 months later. Results: The two larger, most recent trials incorporated similar factorial designs to allow for comparisons between steroids, antivirals, both combined, and placebo, and assessed recovery using validated measures of facial nerve function. In the larger, blinded trial, the numbers needed to treat to achieve complete recovery for patients in the prednisolone and acyclovir groups at 9 months were 7.8 (95% confidence interval [CI] 5.9–13.7) and 18.7 (95% CI 9.5–∞), respectively. The number needed to treat to achieve complete recovery for patients in the valacyclovir plus prednisolone group vs. the prednisolone alone group in the second trial was 14.8 (95% CI 9.1–744.8). Conclusions: Current evidence suggests that prednisolone, an inexpensive and readily available medication, is effective for this common condition, but there was no statistically significant difference observed with acyclovir. Valacyclovir provides minimal added benefit to prednisolone alone.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Grzybowski A.
        • Kaufman M.H.
        Sir Charles Bell (1774–1842): contributions to neuro-ophthalmology.
        Acta Ophthalmol Scand. 2007; 85: 897-901
        • Holland N.J.
        • Weiner G.M.
        Recent developments in Bell's palsy.
        BMJ. 2004; 329: 553-557
        • Salinas R.A.
        • Alvarez G.
        • Ferreira J.
        Corticosteroids for Bell's palsy.
        Cochrane Database Syst Rev. 2004; (idiopathic facial paralysis) (CD001942)
        • Allen D.
        • Dunn L.
        Aciclovir or valaciclovir for Bell's palsy.
        Cochrane Database Syst Rev. 2004; (idiopathic facial paralysis) (CD001869)
        • Engström M.
        • Berg T.
        • Stjernquist-Desatnik A.
        • et al.
        Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial.
        Lancet Neurol. 2008; 7: 993-1000
        • Sullivan F.M.
        • Swan I.R.
        • Donnan P.T.
        • et al.
        Early treatment with prednisolone or acyclovir in Bell's palsy.
        N Engl J Med. 2007; 357: 1598-1607
        • Hato N.
        • Yamada H.
        • Kohno H.
        • et al.
        Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo-controlled study.
        Otol Neurotol. 2007; 28: 408-413
        • Colditz G.A.
        • Miller J.N.
        • Mosteller F.
        How study design affects outcomes in comparisons of therapy.
        Stat Med. 1989; 8: 441-454